
Sign up to save your podcasts
Or
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: dx.doi.org/10.1136/lupus-2022-000763
3.9
1414 ratings
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: dx.doi.org/10.1136/lupus-2022-000763
500 Listeners
38 Listeners
52 Listeners
5 Listeners
8 Listeners
5 Listeners
3 Listeners
2 Listeners
4 Listeners
9 Listeners
38 Listeners
14 Listeners
1 Listeners
52 Listeners
0 Listeners
6 Listeners
11,878 Listeners
3 Listeners
123 Listeners
112,362 Listeners
3 Listeners
26 Listeners
368,457 Listeners
24 Listeners
47,966 Listeners
69 Listeners
33 Listeners
29,193 Listeners
4 Listeners
20,192 Listeners
2 Listeners
45 Listeners
2 Listeners
0 Listeners